Drug Profile
Zaloglanstat - Glenmark Pharmaceuticals Ltd
Alternative Names: GRC-27864; ISC-27864Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Amides; Analgesics; Anti-inflammatories; Antirheumatics; Chlorobenzenes; Fluorobenzenes; Small molecules; Triazoles
- Mechanism of Action Prostaglandin-E synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Pain
- No development reported Inflammation
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in United Kingdom (PO)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Pain(In volunteers) in United Kingdom (PO)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Inflammation in India (PO)